Blacks more likely to present at advanced stage, less likely to receive surgery, have higher mortality at higher residential segregation levels

Findings seen despite the U.S. Preventive Services Task Force revised eligibility criteria

Once operations resumed, decrease seen in new patients screened, proportion of suspicious nodules increased

Current approval of the once-daily tablet indicated for patients who have undergone complete tumor removal

Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i<strong></strong>

Risk varies according to profile of the oral microbiota; risk lower with greater abundance of <em>Spirochaetia</em>, <em>Bacteroidetes</em>

Mutation frequencies of <em>EGFR</em> and <em>KRAS</em> were 30 and 10 percent, respectively, and 23 and 13 percent, respectively, for Mexican and Colombian patients

Restricted mean survival time difference was 0.84 years at 10 years for women undergoing pulmonary resection<strong></strong>

Lung cancer screening at the state level does not correlate with lung cancer burden

People of color face worse outcomes, have lower likelihood of being diagnosed early, receiving surgery